News FDA Clears Nurocheck, Portable Device to Quickly Assess Brain Health FDA Clears Nurocheck, Portable Device to Quickly Assess Brain Health by Marisa Wexler, MS | May 11, 2020 Share this article: Share article via email Copy article link A portable device that can quickly measure electrical activity in the brain and relay it to doctors via a smartphone app, calledĀ the Nurochek system,Ā has been cleared by the United States Food and Drug Administration (FDA) for use as a medical device. Its developer, Headsafe, plans to it soon make this brain assessment system available for use with patients in the U.S., ages 14 and older. āTodayās announcement represents a historic milestone for our company, and we are eager to begin execution of our market launch in the United States,ā Adrian Cohen, CEO and founder of Headsafe, said in a press release. Nurochek works by measuringĀ visual evoked potentialĀ (VEP), the electrical signals that go from the eyes to the brain.Ā When light hits the eyes, it activates specialized light-sensing cells, called photoreceptors. Electrical signals are sent from these cells in the eye to regions of the brain (most notably theĀ visual cortex), where the signals are processed and ultimately translated into images. The system includes a headset worn over the eyes, which connects to a smartphone via an app to transmit data to remote online processing and storage sites known as the cloud.Ā A particular visual stimulus is given the eyes, and thenĀ electroencephalography (EEG) measures the resulting electrical signal from the eye to the brain. The measured EEG data are transmitted for processing and secure cloud storage, Headsafe reports on its website, with the entire process taking about three minutes. Measuring VEP is useful because it can indicate how well neuronsĀ ā the cells that transmit electrical signals within the nervous system ā are functioning within parts of the brain responsible for vision. Abnormalities in VEPs have been associated with Ā conditions that affect the nervous system, including multiple sclerosis, ocular hypertension, diabetes, and traumatic brain injury. Specifically, the FDA gave the Nurochek systemĀ 510(k) clearance, required for commercial use of medical devices in the U.S. The company plans to conduct further research into its use on people with MS and other nervous system disorders. āIn addition to our commercialization efforts in the U.S., we expect to accelerate our research activities to deepen the body of scientific evidence supporting the use of the Nurochek system in the management of specific neurological conditions,ā Cohen added. Headsafe was founded in Sydney in 2017. Print This Page About the Author Marisa Wexler, MS Marisa holds a Master of Science in cellular and molecular pathology from the University of Pittsburgh, where she studied novel genetic drivers of ovarian cancer. Her areas of expertise include cancer biology, immunology, and genetics, and she has worked as a science writing and communications intern for the Genetics Society of America. Tags brain health, FDA
April 18, 2024 News by Marisa Wexler, MS AAN 2024: Sustained myelin, nerve cell gains with long-term CNM-Au8
April 18, 2024 News by Lindsey Shapiro, PhD AAN 2024: Ocrevus benefits Black, Hispanic patients same as whites
April 17, 2024 News by Marisa Wexler, MS AAN 2024: Fertility treatment in MS doesn’t increase relapse risk